Business Context and Reporting Period
Pavmed Inc., an emerging growth company, filed this Form 8-K on January 25, 2018, to report the closing of a partial exercise of an over-allotment option related to its public offering of common stock.
Key Financial Metrics
- Shares Sold: 234,540 shares (Option Shares) at $1.80 per share.
- Total Offering Size: Included 2,415,278 Firm Shares plus the Option Shares.
- Net Proceeds: Approximately $4.3 million from the combined sale of Firm Shares and Option Shares after underwriting discounts and offering expenses.
- Underwriter: Dawson James Securities, Inc.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, operating cash flow, or specific debt levels.
Material Changes
This filing represents a capital raise event rather than a change in operating performance. The material change is the increase in the company's cash position by approximately $4.3 million following the closing of the over-allotment option exercise.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction. The primary event is the consummation of the securities sale.
Investor Verification Checklist
- Verify the final total number of shares outstanding post-offering.
- Confirm the specific allocation of the $4.3 million net proceeds in the company's balance sheet.
- Review the full underwriting agreement for details on lock-up periods or additional obligations.
- Check subsequent filings for how the raised capital is being deployed (e.g., R&D, working capital).